351. Group of longitudinal adverse event patterns after the fourth dose of COVID-19 vaccination with a latent class analysis
- Author
-
Chika Yamamoto, Yurie Kobashi, Takeshi Kawamura, Yoshitaka Nishikawa, Hiroaki Saito, Fumiya Oguro, Tianchen Zhao, Morihito Takita, Toyoaki Sawano, Akihiko Ozaki, Toshiki Abe, Naomi Ito, Yudai Kaneko, Aya Nakayama, Masatoshi Wakui, Tatsuhiko Kodama, and Masaharu Tsubokura
- Subjects
COVID-19 ,vaccination ,adverse events ,latent class analysis ,Fukushima cohort ,Public aspects of medicine ,RA1-1270 - Abstract
IntroductionVaccination has been implemented as a useful measure to combat the COVID-19 pandemic. However, there is a tendency for individuals to avoid vaccination due to the possibility of adverse events, making it important to investigate the relationship between COVID-19 vaccines and their adverse events. This study explored longitudinal adverse event patterns and factors that influence adverse events following the second to fourth doses of the COVID-19 vaccine through a latent class analysis.MethodsParticipants were recruited from the Fukushima Prefecture and included individuals who had completed four doses of the COVID-19 mRNA vaccine. This study utilized data from questionnaire surveys and blood collection conducted between September 2021 and November 2022. In the questionnaire, factors such as sex, age, medical history, medication, type of vaccine administered, and adverse events following vaccination were recorded. Additionally, in the blood data, serological tests [IgG(S)] and cellular immune responses (T-spot) were measured. Descriptive statistics, latent class analysis, multivariable logistic regression, and multiple regression analyses were performed to identify the longitudinal adverse event patterns and influencing factors. By analyzing adverse events over time, we identified two distinct groups: those less prone to experiencing adverse events (Group 1) and those more susceptible (Group 2) to latent class analysis.ResultsA total of 1,175 participants were included after excluding those without any adverse events. The median age of the participants in Group 1 was 70 years, and in Group 2 it was 51 years. The proportion of female participants was 298 in Group 1 and 353 in Group 2. Patients in Group 2 were significantly younger (p
- Published
- 2024
- Full Text
- View/download PDF